Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
Ícono de BMS, studio Reclutando

Recruiting

ID del estudio CN012-0046  |   NCT07140913

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Resumen

  • Phase 3
  • Ícono de género masculino y femenino
  • 18-65
  • 22
  • Ícono de BMS, studio Reclutando
    Recruiting

Descripción general

The purpose of this study is to evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolar-I Disorder.

Imprimir Imprimir
Email Correo electrónico

Centro de reclutamiento más cercano

Criterios clave de elegibilidad

Criterios de inclusión

Criterios de inclusión Icon
:
  • Individuals have a primary diagnosis of Bipolar-I disorder established by a comprehensive psychiatric evaluation based on the DSM-5-TR criteria and confirmed by the Mini International Neuropsychiatric Interview (MINI) version 7.0.2 Standard.
    1. Individual is experiencing an acute exacerbation or relapse of manic episode, with or without mixed features (≤ 3 weeks).
      1. The individual requires hospitalization for the acute exacerbation or relapse of mania.
        1. Body mass index ≥ 18 and ≤ 40 kg/m2
          1. Currently experiencing an acute episode of mania or mania with mixed features with a therapeutic dose of lithium, valproate, or lamotrigine. The dose of the mood stabilizer must have remained stable for at least two weeks prior to screening. Additionally, participants on valproate must have been receiving treatment with valproate for a minimum of seven months.
            1. YMRS Total Score of ≥ 18 at Screening and at Baseline, and < 20% reduction in YMRS from screening to baseline.
              1. Clinical Global Impression Severity scale (CGI-BP) ≥ 4

                Criterios de exclusión

                Criterios de exclusión Icon
                :
                • Any primary DSM-5-TR disorder other than BP-I within 12 months before screening (confirmed using MINI version 7.0.2 Standard) including BP-I depression, BP-I with rapid cycling, first manic episode, BP-II, and major depressive disorder.
                  1. Individual has a DSM-5-TR diagnosis of moderate to severe substance use disorder (except tobacco use disorder) within the 12 months before screening (confirmed using MINI version 7.0.2 Standard at screening), or current use as determined by urine toxicology screen or alcohol test.
                    1. Risk for suicidal behavior at screening as determined by the investigator's clinical assessment and the C-SSRS with an answer "Yes" to item 4 or 5 within 6 months before screening or between screening and baseline, or suicide attempt within 12 months before screening, or between screening and baseline
                      1. History of irritable bowel syndrome (with or without constipation) or any serious constipation requiring treatment within the last 6 months.
                        1. History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma.
                          1. Participants with HIV, cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections based on either medical history or the LFT results.
                            1. Elevations in hepatic transaminases at screening ≥ 2 × ULN for ALT and AST and/or bilirubin > 1.5× ULN, unless in the context of Gilbert's syndrome.
                              1. All grades of hepatic impairment (mild [Child-Pugh Class A], moderate [Child-Pugh Class B], and severe [Child-Pugh Class C]).
                                Información Adicional *
                                • Other protocol-defined Inclusion/Exclusion criteria apply.

                                  Opciones de tratamiento

                                  Brazos del estudio

                                  INTERVENCIÓN ASIGNADA

                                  Brazos del estudio

                                  Experimental: KarXT + Lithium, Valproate, or Lamotrigine

                                  INTERVENCIÓN ASIGNADA

                                  Brazos del estudio

                                  Placebo Comparator: Placebo + Lithium, Valproate, or Lamotrigine

                                  INTERVENCIÓN ASIGNADA
                                  Dé el primer paso para ver si es compatible con un estudio clínico - Verifique su elegibilidad
                                  Verifique su elegibilidad
                                  Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
                                  Compatibilizar con un estudio
                                  Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
                                  Seleccione una ubicación del centro del estudio
                                  Seleccione una ubicación del centro del estudio que sea conveniente para usted
                                  Registrarse
                                  Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

                                  Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias